GSKs RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 1849 Years at Increased Risk
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has expanded the approved age indication of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) to adults...